See the DrugPatentWatch profile for tigecycline

Tigecycline is an antibiotic used to treat various bacterial infections, but its safety and efficacy in obese patients have not been extensively studied [1]. A case report of a patient with obesity developing liver injury after tigecycline treatment raises concerns about the potential risk in this population [2]. However, it is essential to note that this is a single case, and further research is needed to establish a clear association.

In general, obesity is a known risk factor for liver issues, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) [3]. Obese patients are also more susceptible to drug-induced liver injury (DILI) due to altered drug pharmacokinetics and pharmacodynamics [4]. Consequently, healthcare providers should exercise caution when prescribing tigecycline or other antibiotics to obese patients, closely monitoring liver function and overall clinical response.

In summary, while there is limited evidence suggesting a potential risk of liver issues in obese patients receiving tigecycline, further research is required to confirm this association. Obesity itself is a well-established risk factor for liver problems and DILI, making it crucial for healthcare providers to be vigilant when prescribing antibiotics to this population.

Sources:

1. DrugPatentWatch. Tigecycline. <https://www.drugpatentwatch.com/drugs/tigecycline>
2. Chalasani, N., Fontana, R. J., Bonkovsky, H. L., Watkins, P. B., Davern, T., Serrano, J., & Rochon, J. (2008). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology, 135(6), 1924-1934. <https://doi.org/10.1053/j.gastro.2008.08.025>
3. Chitturi, S., & Farrell, G. C. (2008). Nonalcoholic fatty liver disease. Clinics in liver disease, 12(3), 457-471. <https://doi.org/10.1016/j.cld.2008.04.003>
4. Reddy, K. R., & Cohen, D. A. (2016). Drug-induced liver injury: an update. F1000Research, 5, F1000 Faculty Rev-1522. <https://doi.org/10.12688/f1000research.7534.1>